arrow
J

Jan Budczies

national center for tumor diseases
H指数:65
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive Liquid Biopsy Testing in Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Patients: First Results from Routine Clinical Practice

转移性激素受体阳性HER2阴性乳腺癌患者中的全面液体活检检测:来自常规临床实践的首批结果

2026-05-010
PRE
Spatial transcriptomics reveals a molecular tumor budding signature in head and neck cancer

空间转录组学揭示头颈癌中分子肿瘤出芽特征

2026-04-150
OAAI
Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing

在常规医疗保健中为癌症患者实施全基因组与转录组测序:成本核算的全面指南

2026-04-070
OAAI
Correction: Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples

更正:对1233例FFPE实体瘤样本进行诊断性全转录组测序

2026-03-020
OAAI
Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples

在1233例FFPE实体瘤样本中进行的诊断性全转录组测序

2026-01-140
OAAI
EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer

EGFR介导的局部侵袭性和西妥昔单抗治疗反应在头颈癌中的研究

2025-03-220
OA
Clinical Implementation of a High-Throughput Automated Comprehensive Genomic Profiling Test TruSight Oncology 500 HT
2025-02-010
OAAI
Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas
2024-11-290
OA
Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study

剖析肺腺癌中基于AI的突变预测: 一项全面的现实研究

2024-11-011
PRE
Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)

NEONAX试验的探索性生物标志物分析,用于预测可切除胰腺导管腺癌患者(rPDAC Pts)对围手术期(PO)和辅助性(A)Gem-nabPac化疗(CTX)的治疗反应

2024-09-010
PRE